Wai Chun Bio-Technology Limited disclosed that on 27 April 2026 it issued 166.67 million new ordinary shares upon conversion of HK$10.00 million in convertible bonds at an exercise price of HK$0.01 per share.

The newly allotted shares equate to 93.38 % of the company’s 178.48 million issued shares outstanding before the transaction. Following the conversion, Wai Chun Biotec’s total issued share capital rose to 345.14 million shares, effectively expanding the share base by 93.38 %.

No treasury shares were created, sold, or cancelled in connection with the transaction, and the company reported no share repurchases during the period.

The board confirmed that the share issuance complied with all relevant Hong Kong Stock Exchange listing rules and regulatory requirements, and that the full subscription proceeds have been received.